Drug intelligence / Profile preview

NEO-201 bispecific antibody

Development stage: Preclinical
Lead developer: Precision Biologics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

NEO-201 bispecific antibody is an engineered therapeutic candidate developed by Precision Biologics. It is derived from the NEO-201 monoclonal antibody, which specifically targets truncated O-glycans (such as Core 1 and Core 2 O-glycans) that are expressed on various solid and hematological tumors but absent in healthy tissues. As a bispecific antibody, it is designed to simultaneously bind to these tumor-associated glycans and a second target, typically an immune effector cell, to facilitate targeted tumor cell killing. It is currently in preclinical development for the treatment of various tumor types.

Other names: NEO-201 Engineered (Bispecific)

Targets

Carcinoembryonic antigen-related cell adhesion molecule 5/6 tumor-associated O-glycan variants

Beyond the preview

Go deeper on NEO-201 bispecific antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEO-201 bispecific antibody.

Explore the full profile